Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Stock Information for Evogene Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evogene Ltd.

Evogene Releases CEO Letter to Shareholders
Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics
Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds
Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI(TM)
Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer  

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.